Review of 10 years of research on breast cancer patients: Focus on indoleamine 2,3-dioxygenase

Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer

(2020) Lijuan Wei et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan

(2019) Kashif Asghar et al.   Cancer Management and Research

Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy

(2019) Concetta Elisa Onesti et al.   Journal of Translational Medicine

Chemoresistance was correlated with elevated expression and activity of indoleamine 2,3-dioxygenase in breast cancer

(2019) Yang Zhao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer

(2018) Fangxuan Li et al.   CANCER BIOLOGY & THERAPY

Expression of programmed cell death protein 1 (PD-1) and indoleamine 2,3-dioxygenase (IDO) in the tumor microenvironment and in tumor-draining lymph nodes of breast cancer

(2018) Qian Ye et al.   HUMAN PATHOLOGY

IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1

(2018) Erik A. Dill et al.   MODERN PATHOLOGY

High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer

(2018) Lijuan Wei et al.   Frontiers in Immunology

Indoleamine-2,3-dioxygenase and Interleukin-6 associated with tumor response to neoadjuvant chemotherapy in breast cancer

(2017) Fangxuan Li et al.   Oncotarget

Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer

(2017) Sewha Kim et al.   Journal of Cancer

Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer

(2017) Dyah L. Dewi et al.   OncoImmunology

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer

(2017) Daniel E. Carvajal-Hausdorf et al.   Journal for ImmunoTherapy of Cancer

Effect of the association of 1-methyl-DL-tryptophan with paclitaxel on the expression of indoleamine 2,3-dioxygenase in cultured cancer cells from patients with breast cancer

(2015) Maria Letícia Baptista Salvadori et al.   MEDICAL ONCOLOGY

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

(2015) Yong Wha Moon et al.   Journal for ImmunoTherapy of Cancer

Analysis of Indoleamine 2-3 Dioxygenase (IDO) and EGFR Co-expression in Breast Cancer Tissue by Immunohistochemistry

(2014) Wei-Wei Bi et al.   Asian Pacific Journal of Cancer Prevention

IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis

(2014) M. T. Isla Larrain et al.   TUMOR BIOLOGY

Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease

(2013) Amos A. Fatokun et al.   AMINO ACIDS

Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry

(2013) Hatem Soliman et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer

(2013) J. Yu et al.   JOURNAL OF IMMUNOLOGY

Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation

(2012) Vera Levina et al.   Clinical & Developmental Immunology

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

(2012) Richard Metz et al.   OncoImmunology

Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T CellsIn Situand Lymph Node Metastasis

(2011) Jinpu Yu et al.   Clinical & Developmental Immunology

High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma

(2011) Jocelyne Jacquemier et al.   INTERNATIONAL JOURNAL OF CANCER

Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells

(2011) Jingyan Sun et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

(2010) X. Liu et al.   BLOOD

Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors

(2010) H. K. Koblish et al.   MOLECULAR CANCER THERAPEUTICS

Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase

(2009) Sara A. Rafice et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer

(2009) Aaron S Mansfield et al.   BMC CANCER

IDO and outcomes in ovarian cancer

(2009) Brad H. Nelson   GYNECOLOGIC ONCOLOGY

Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma

(2009) Tomoko Inaba et al.   GYNECOLOGIC ONCOLOGY

The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer

(2009) Yan-Fang Gao et al.   Journal of Translational Medicine

Exploring the mechanism of tryptophan 2,3-dioxygenase

(2008) Sarah J. Thackray et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

(2008) Stefan Löb et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape

(2008) Jessica B. Katz et al.   IMMUNOLOGICAL REVIEWS

Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway

(2008) Helen J. Ball et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY